XTX Topco’s vTv Therapeutics VTVT Stock Holding History

XTX Topco’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-501	Closed	-$46K	–	1089
2021 Q2	$46K	Buy	501 +222	+80%	+$22.5K	0.02%	731
2021 Q1	$31K	Buy	+279	New	+$27.4K	0.02%	647

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WAG

Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

XTX Topco's VTVT Position: Q3 2021 in Review

XTX Topco sold out of vTv Therapeutics (VTVT) in Q3 2021, closing a stake of 501 shares — an estimated $46K sold.

XTX Topco first reported a position in VTVT in Q1 2021 and held it in 2 quarters. The position peaked at $46K in Q2 2021. 31 funds tracked by Wall St. Rank hold VTVT as of Q3 2021.

XTX Topco reported no remaining vTv Therapeutics position as of Q3 2021 after selling out during the quarter.
XTX Topco sold 501 vTv Therapeutics shares in Q3 2021, an estimated $46K.
XTX Topco first reported a position in vTv Therapeutics in Q1 2021 and held it in 2 quarters.
XTX Topco's vTv Therapeutics position peaked at $46K in Q2 2021.
31 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2021.

Based on XTX Topco's 13F filing for Q3 2021, filed 12 Nov 2021.